Developer docs
API playgroundTry for free, no card

Search company profiles

Recursion Pharmaceuticals

Full company profile

uuid00007ed

Namestring
Recursion Pharmaceuticals
Legal namestring
Recursion Pharmaceuticals, Inc.
Websiteurl
recursion.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Recursion Pharmaceuticals is a clinical-stage TechBio company that applies artificial intelligence and a large proprietary multimodal dataset to industrialize drug discovery and development. Founded in 2013 and headquartered in Salt Lake City, the company operates Recursion OS, an end-to-end platform that integrates automated wet-lab experimentation with purpose-built AI foundation models spanning target identification, generative chemistry design, and clinical trial optimization. The platform is backed by more than 50 petabytes of proprietary biological and chemical data, automated laboratories processing up to 2.2 million samples per week, and BioHive-2, a supercomputer built with NVIDIA containing 504 H100 GPUs. Recursion has released multiple foundation models (Phenom-Beta, OpenPhenom-S/16, TxPert, TxFM, Boltz-2, MolE) and an LLM-orchestrated workflow engine called LOWE.

The company's commercial model is partnership-driven B2B enterprise sales targeting large pharmaceutical companies. Recursion generates revenue through multi-year collaboration agreements with upfront fees, research and development milestones, and tiered royalties on net sales, with named partners including Roche/Genentech (up to 40 programs, $150M upfront), Sanofi (up to 15 targets, $100M upfront, up to $5.2B potential milestones), Bayer (up to 7 oncology programs, $80M upfront, up to $1.5B potential payments), and Merck KGaA ($20M upfront, up to $674M in milestones). A wholly-owned pipeline of five clinical-stage programs (REC-4881, REC-617, REC-1245, REC-3565, REC-4539) and approximately 15 discovery programs provides optionality for direct commercialization. FY 2025 revenue was $74.7M, up 26.9% YoY, against a net loss of ~$644.8M; the company held $665.2M in cash at Q1 2026, providing runway into early 2028.

Short descriptiontext

Recursion Pharmaceuticals is a clinical-stage TechBio company that uses AI and over 50 petabytes of proprietary biological data to industrialize drug discovery, partnering with major pharmaceutical firms on multi-program collaborations and advancing five wholly-owned clinical programs in oncology and rare disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSalt Lake City, United States
HQ citystring
Salt Lake City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, drug discovery platform, computational biology, foundation models biology, biotechnology research
Industry5 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
AI Drug Discovery Platform
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model6 records
1Partnership Revenue - Sanofi
TypeLicensing Royalties
Description

Strategic research collaboration with Sanofi to develop AI-driven pipeline of precision-engineered small molecule medicines. Received $100M upfront, with potential for up to $5.2B in aggregate milestone payments plus tiered royalties on net sales ranging from high-single-digits to mid-teens. Partnership covers up to 15 novel targets in oncology and immunology.

recursion.com
2Partnership Revenue - Roche/Genentech
TypeLicensing Royalties
Description

Multi-year strategic collaboration in neuroscience and oncology. Received $150M upfront. Each of up to 40 programs could yield more than $300M in development, commercialization and net sales milestones for Recursion, plus tiered royalties on net sales.

recursion.com
3Partnership Revenue - Bayer
TypeLicensing Royalties
Description

Precision oncology collaboration covering up to seven oncology programs. Received $80M upfront and equity investment. Potential success-based payments up to $1.5B plus royalties on net sales.

recursion.com
4Partnership Revenue - Merck KGaA
TypeLicensing Royalties
Description

Multi-year collaboration in oncology and immunology. Received $20M upfront with discovery, development, regulatory and sales-based milestone payments up to $674M aggregate if all milestones for three initial programs are achieved.

recursion.com
5Platform Licensing - BioNeMo
TypeLicensing Royalties
Description

License of Phenom-Beta foundation model through NVIDIA's BioNeMo platform for external commercial and non-commercial use.

recursion.com
6Milestone Revenue
TypeTransaction Fee
Description

Revenue recognized from completion of research milestones under partnership agreements. Q4 2025 included $30M milestone payment from Roche for second phenomap. Fifth milestone achieved with Sanofi totaling $134M in payments to date.

finance.yahoo.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1Recursion OS
Description

AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system

recursion.com
+4 more records
Core offering1 text field

Recursion Pharmaceuticals develops and sells Recursion OS, an AI-native, end-to-end drug discovery and development platform that integrates automated wet-lab experimentation with proprietary AI models and foundation models. The platform spans from target identification through clinical development, generating one of the world's largest fit-for-purpose proprietary biological and chemical datasets exceeding 50 petabytes. Revenue is generated primarily through strategic partnership agreements with large pharmaceutical companies (Roche/Genentech, Sanofi, Bayer, Merck KGaA) featuring upfront payments, milestone payments, and royalties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 43-53% reduction in polyp burden in Phase 2 FAP trial with REC-4881
+6 more records
Product overview1 text field

Recursion Pharmaceuticals is a clinical-stage TechBio company offering Recursion OS, an AI-native, end-to-end drug discovery and development platform that integrates biology, chemistry, and clinical development. The platform consists of multiple interconnected components: Recursion OS serves as the core system connecting physical experimentation (wet lab) with computational analysis (in silico), supported by BioHive-2 supercomputer infrastructure. Key sub-products include LOWE (LLM-orchestrated workflow engine with natural language interface), Maps of Biology and Chemistry for target identification, MatchMaker for compound-target interaction prediction, and generative chemistry models for molecule design. Foundation models including Phenom-Beta, OpenPhenom-S/16, TxPert, TxFM, Boltz-2, and MolE power specific capabilities across imaging, transcriptomics, and molecular property prediction. The platform enables users to discover novel targets, design optimized compounds, and advance candidates through the drug development pipeline with reported efficiency gains of up to 3X faster than traditional industry averages.

Product and service1 record
1Recursion OS
Scale indicator24 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-01
Description

Expanded collaboration leveraging generative AI capabilities including Gemini models, advanced computing resources, BigQuery for improved search and access. OpenPhenom-S/16 foundation model released on Google Cloud's Vertex AI Model Garden and Hugging Face.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-05-01
Description

Multi-year agreement accessing hundreds of thousands of de-identified records including Exome+ genomic data and longitudinal health records. Used to train causal AI models and design biomarker strategies across broad disease areas. >200k non-oncology clinico-genomic records accessed to date.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-01
Description

Precision oncology collaboration covering up to seven oncology programs. $80M upfront and equity investment. Potential success-based payments up to $1.5B plus royalties on net sales. Bayer became first external beta user of LOWE platform.

4Tempus
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-11-01
Description

Preferred access to one of world's largest proprietary de-identified patient-centric oncology datasets spanning DNA, RNA, health records. >20 petabytes of data to support discovery of biomarker-enriched therapeutics through training of causal AI models.

recursion.com
5Merck KGaA, Darmstadt, Germany
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-01
Description

Multi-year collaboration leveraging Recursion's AI-driven precision drug design capabilities with Merck KGaA's disease expertise in oncology and immunology. $20M upfront, potential up to $674M in aggregate milestones for three initial programs.

recursion.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-07-12
Description

Strategic partnership backed by $50M investment to advance AI-enabled drug discovery. NVIDIA provides computing expertise and cloud platform to scale foundation models in biology and chemistry. Recursion's Phenom-Beta model released on NVIDIA BioNeMo platform. BioHive-2 supercomputer built with NVIDIA DGX H100 systems.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

AI-driven pipeline of precision-engineered small molecule medicines for up to 15 novel targets in oncology and immunology. $100M upfront, potential $5.2B in aggregate milestone payments plus tiered royalties (high-single-digits to mid-teens). Five programs advanced through initial milestones.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-12-07
Description

Multi-year strategic collaboration in neuroscience and oncology. Recursion provides Recursion OS and Maps of Biology with extensive single-cell perturbation screening data from partners. Up to 40 programs possible over decade or longer. $150M upfront, each program could yield >$300M in milestones plus royalties.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-06-01
Description

Multi-year collaboration for tech-enabled drug discovery announced June 2021.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-05-01
Description

Co-development and co-ownership joint venture to investigate treatments for rare diseases. Selected ENPP1 as target for hypophosphatasia (HPP). Combines Rallybio's clinical knowledge with Recursion's AI platform.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-enabled drug discovery platform company using human-centric data and computation to accelerate drug development. Comparable in offering integrated AI drug discovery capabilities to pharma partners.

TypeDirect peer
Description

AI small molecule discovery company using convolutional neural networks for structure-based drug design. Direct competitor in AI-driven hit identification and lead optimization.

TypeDirect peer
Description

AI-powered drug discovery company combining quantum physics, AI, and robotics for small molecule and crystal structure prediction. Comparable in offering AI-driven drug discovery to large pharma.

TypeDirect peer
Description

Computational chemistry and physics-based simulation platform serving pharma with software and collaborative drug discovery. Comparable in offering computational platforms to large pharma for molecular design.

TypeEmerging player
Description

AI-enabled antibody discovery platform partnering with pharma for therapeutic antibody development. Adjacent in applying AI/ML to biologics discovery with similar partnership-driven model.

TypeDirect peer
Description

AI-driven drug discovery company combining ML with high-throughput biology to discover and develop therapeutics. Direct competitor in the TechBio space with similar target ID and platform approach.

TypeDirect peer
Description

AI-driven drug discovery company with end-to-end platform spanning target identification through clinical development. Comparable AI-native PharmaTech business model with partnered and internal pipeline.

TypeDirect peer
Description

AI-driven drug discovery company using knowledge graphs and ML for target identification and drug repurposing. Comparable AI-platform approach targeting pharma partnerships and internal pipeline.

9Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed AI drug discovery company spun out of DeepMind. Direct competitor pursuing AI-native drug design with deep-learning foundation models for biology.

TypeEmerging player
Description

AI-driven drug discovery company using foundation models for chemistry and physics-based simulation. Direct emerging competitor in AI-native small molecule design.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability11 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature13 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds19 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors38 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Recursion Pharmaceuticals

AI Drug Discovery Platformrecursion.com

Recursion Pharmaceuticals is a clinical-stage TechBio company that uses AI and over 50 petabytes of proprietary biological data to industrialize drug discovery, partnering with major pharmaceutical firms on multi-program collaborations and advancing five wholly-owned clinical programs in oncology and rare disease.

What Recursion Pharmaceuticals does

Recursion Pharmaceuticals is a clinical-stage TechBio company that applies artificial intelligence and a large proprietary multimodal dataset to industrialize drug discovery and development. Founded in 2013 and headquartered in Salt Lake City, the company operates Recursion OS, an end-to-end platform that integrates automated wet-lab experimentation with purpose-built AI foundation models spanning target identification, generative chemistry design, and clinical trial optimization. The platform is backed by more than 50 petabytes of proprietary biological and chemical data, automated laboratories processing up to 2.2 million samples per week, and BioHive-2, a supercomputer built with NVIDIA containing 504 H100 GPUs. Recursion has released multiple foundation models (Phenom-Beta, OpenPhenom-S/16, TxPert, TxFM, Boltz-2, MolE) and an LLM-orchestrated workflow engine called LOWE.

The company's commercial model is partnership-driven B2B enterprise sales targeting large pharmaceutical companies. Recursion generates revenue through multi-year collaboration agreements with upfront fees, research and development milestones, and tiered royalties on net sales, with named partners including Roche/Genentech (up to 40 programs, $150M upfront), Sanofi (up to 15 targets, $100M upfront, up to $5.2B potential milestones), Bayer (up to 7 oncology programs, $80M upfront, up to $1.5B potential payments), and Merck KGaA ($20M upfront, up to $674M in milestones). A wholly-owned pipeline of five clinical-stage programs (REC-4881, REC-617, REC-1245, REC-3565, REC-4539) and approximately 15 discovery programs provides optionality for direct commercialization. FY 2025 revenue was $74.7M, up 26.9% YoY, against a net loss of ~$644.8M; the company held $665.2M in cash at Q1 2026, providing runway into early 2028.

Recursion Pharmaceuticals firmographics

Firmographics
Name
Recursion Pharmaceuticals
Legal name
Recursion Pharmaceuticals, Inc.
Website
https://recursion.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Recursion Pharmaceuticals is a clinical-stage TechBio company that uses AI and over 50 petabytes of proprietary biological data to industrialize drug discovery, partnering with major pharmaceutical firms on multi-program collaborations and advancing five wholly-owned clinical programs in oncology and rare disease.
Ownership category
akta.pro rank

Recursion Pharmaceuticals industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • AI drug discovery
  • Drug discovery platform
  • Computational biology
  • Foundation models biology
  • Biotechnology research

Where Recursion Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Salt Lake City
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Recursion Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Partnership Revenue - Sanofi: Strategic research collaboration with Sanofi to develop AI-driven pipeline of precision-engineered small molecule medicines. Received $100M upfront, with potential for up to $5.2B in aggregate milestone payments plus tiered royalties on net sales ranging from high-single-digits to mid-teens. Partnership covers up to 15 novel targets in oncology and immunology.
  2. Partnership Revenue - Roche/Genentech: Multi-year strategic collaboration in neuroscience and oncology. Received $150M upfront. Each of up to 40 programs could yield more than $300M in development, commercialization and net sales milestones for Recursion, plus tiered royalties on net sales.
  3. Partnership Revenue - Bayer: Precision oncology collaboration covering up to seven oncology programs. Received $80M upfront and equity investment. Potential success-based payments up to $1.5B plus royalties on net sales.
  4. Partnership Revenue - Merck KGaA: Multi-year collaboration in oncology and immunology. Received $20M upfront with discovery, development, regulatory and sales-based milestone payments up to $674M aggregate if all milestones for three initial programs are achieved.
  5. Platform Licensing - BioNeMo: License of Phenom-Beta foundation model through NVIDIA's BioNeMo platform for external commercial and non-commercial use.
  6. Milestone Revenue: Revenue recognized from completion of research milestones under partnership agreements. Q4 2025 included $30M milestone payment from Roche for second phenomap. Fifth milestone achieved with Sanofi totaling $134M in payments to date.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Recursion Pharmaceuticals product offering

Product offering

Core offering

Recursion Pharmaceuticals develops and sells Recursion OS, an AI-native, end-to-end drug discovery and development platform that integrates automated wet-lab experimentation with proprietary AI models and foundation models. The platform spans from target identification through clinical development, generating one of the world's largest fit-for-purpose proprietary biological and chemical datasets exceeding 50 petabytes. Revenue is generated primarily through strategic partnership agreements with large pharmaceutical companies (Roche/Genentech, Sanofi, Bayer, Merck KGaA) featuring upfront payments, milestone payments, and royalties.

Product overview

Recursion Pharmaceuticals is a clinical-stage TechBio company offering Recursion OS, an AI-native, end-to-end drug discovery and development platform that integrates biology, chemistry, and clinical development. The platform consists of multiple interconnected components: Recursion OS serves as the core system connecting physical experimentation (wet lab) with computational analysis (in silico), supported by BioHive-2 supercomputer infrastructure. Key sub-products include LOWE (LLM-orchestrated workflow engine with natural language interface), Maps of Biology and Chemistry for target identification, MatchMaker for compound-target interaction prediction, and generative chemistry models for molecule design. Foundation models including Phenom-Beta, OpenPhenom-S/16, TxPert, TxFM, Boltz-2, and MolE power specific capabilities across imaging, transcriptomics, and molecular property prediction. The platform enables users to discover novel targets, design optimized compounds, and advance candidates through the drug development pipeline with reported efficiency gains of up to 3X faster than traditional industry averages.

Differentiator

Problem solved

Functional benefit

Brands

  • Recursion OS: AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system
  • LOWE
  • BioHive-2
  • Altitude Lab
  • Exscientia

Products and services

  • Recursion OS

Quantifiable outcome

  • 43-53% reduction in polyp burden in Phase 2 FAP trial with REC-4881
  • +6 more outcomes

Companies that use Recursion Pharmaceuticals

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Recursion Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability11 records

Feature13 records

Recursion Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, flagship and minor.

  • Google CloudcoreTechnology or Integration · 1 October 2024Expanded collaboration leveraging generative AI capabilities including Gemini models, advanced computing resources, BigQuery for improved search and access. OpenPhenom-S/16 foundation model released on Google Cloud's Vertex AI Model Garden and Hugging Face.
  • HelixcoreTechnology or Integration · 1 May 2024Multi-year agreement accessing hundreds of thousands of de-identified records including Exome+ genomic data and longitudinal health records. Used to train causal AI models and design biomarker strategies across broad disease areas. >200k non-oncology clinico-genomic records accessed to date.
  • Bayer PharmaceuticalscoreStrategic or Co-development Partner · 1 November 2023Precision oncology collaboration covering up to seven oncology programs. $80M upfront and equity investment. Potential success-based payments up to $1.5B plus royalties on net sales. Bayer became first external beta user of LOWE platform.
  • TempuscoreTechnology or Integration · 1 November 2023Preferred access to one of world's largest proprietary de-identified patient-centric oncology datasets spanning DNA, RNA, health records. >20 petabytes of data to support discovery of biomarker-enriched therapeutics through training of causal AI models.
  • Merck KGaA, Darmstadt, GermanycoreStrategic or Co-development Partner · 1 September 2023Multi-year collaboration leveraging Recursion's AI-driven precision drug design capabilities with Merck KGaA's disease expertise in oncology and immunology. $20M upfront, potential up to $674M in aggregate milestones for three initial programs.
  • NVIDIAcoreTechnology or Integration · 12 July 2023Strategic partnership backed by $50M investment to advance AI-enabled drug discovery. NVIDIA provides computing expertise and cloud platform to scale foundation models in biology and chemistry. Recursion's Phenom-Beta model released on NVIDIA BioNeMo platform. BioHive-2 supercomputer built with NVIDIA DGX H100 systems.
  • SanofiflagshipStrategic or Co-development Partner · 1 January 2022AI-driven pipeline of precision-engineered small molecule medicines for up to 15 novel targets in oncology and immunology. $100M upfront, potential $5.2B in aggregate milestone payments plus tiered royalties (high-single-digits to mid-teens). Five programs advanced through initial milestones.
  • Roche & GenentechflagshipStrategic or Co-development Partner · 7 December 2021Multi-year strategic collaboration in neuroscience and oncology. Recursion provides Recursion OS and Maps of Biology with extensive single-cell perturbation screening data from partners. Up to 40 programs possible over decade or longer. $150M upfront, each program could yield >$300M in milestones plus royalties.
  • MILA (Montreal Institute for Learning Algorithms)minorStrategic or Co-development Partner · 1 June 2021Multi-year collaboration for tech-enabled drug discovery announced June 2021.
  • RallybiominorStrategic or Co-development Partner · 1 May 2019Co-development and co-ownership joint venture to investigate treatments for rare diseases. Selected ENPP1 as target for hypophosphatasia (HPP). Combines Rallybio's clinical knowledge with Recursion's AI platform.

Scale indicators24 records

Recent moves9 records

Expansion highlights6 records

Recursion Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Valo Health: AI-enabled drug discovery platform company using human-centric data and computation to accelerate drug development. Comparable in offering integrated AI drug discovery capabilities to pharma partners.
  • Atomwise: AI small molecule discovery company using convolutional neural networks for structure-based drug design. Direct competitor in AI-driven hit identification and lead optimization.
  • XtalPi: AI-powered drug discovery company combining quantum physics, AI, and robotics for small molecule and crystal structure prediction. Comparable in offering AI-driven drug discovery to large pharma.
  • Schrödinger: Computational chemistry and physics-based simulation platform serving pharma with software and collaborative drug discovery. Comparable in offering computational platforms to large pharma for molecular design.
  • Insitro: AI-driven drug discovery company combining ML with high-throughput biology to discover and develop therapeutics. Direct competitor in the TechBio space with similar target ID and platform approach.
  • Insilico Medicine: AI-driven drug discovery company with end-to-end platform spanning target identification through clinical development. Comparable AI-native PharmaTech business model with partnered and internal pipeline.
  • BenevolentAI: AI-driven drug discovery company using knowledge graphs and ML for target identification and drug repurposing. Comparable AI-platform approach targeting pharma partnerships and internal pipeline.
  • Isomorphic Labs: Alphabet-backed AI drug discovery company spun out of DeepMind. Direct competitor pursuing AI-native drug design with deep-learning foundation models for biology.

Emerging players

  • AbCellera: AI-enabled antibody discovery platform partnering with pharma for therapeutic antibody development. Adjacent in applying AI/ML to biologics discovery with similar partnership-driven model.
  • Iambic (formerly Entasis Therapeutics): AI-driven drug discovery company using foundation models for chemistry and physics-based simulation. Direct emerging competitor in AI-native small molecule design.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Recursion Pharmaceuticals social profiles

Digital presence

Recursion Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Recursion Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles19 records

Recursion Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Recursion Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds19 records

Investors38 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Recursion Pharmaceuticals M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Recursion Pharmaceuticals

What does Recursion Pharmaceuticals do?

Recursion Pharmaceuticals develops and sells Recursion OS, an AI-native, end-to-end drug discovery and development platform that integrates automated wet-lab experimentation with proprietary AI models and foundation models. The platform spans from target identification through clinical development, generating one of the world's largest fit-for-purpose proprietary biological and chemical datasets exceeding 50 petabytes. Revenue is generated primarily through strategic partnership agreements with large pharmaceutical companies (Roche/Genentech, Sanofi, Bayer, Merck KGaA) featuring upfront payments, milestone payments, and royalties.

Is Recursion Pharmaceuticals a public or private company?

Recursion Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Recursion Pharmaceuticals founded?

Recursion Pharmaceuticals was founded in 2013. It employs 501 to 1,000 people.

Where is Recursion Pharmaceuticals based?

Recursion Pharmaceuticals is headquartered in Salt Lake City, United States, in the North America region.

How does Recursion Pharmaceuticals make money?

Six revenue lines are on record. Partnership Revenue - Sanofi is the primary driver. The others are partnership Revenue - Roche/Genentech, partnership Revenue - Bayer, partnership Revenue - Merck KGaA, platform Licensing - BioNeMo and milestone Revenue.

Who are Recursion Pharmaceuticals's main competitors?

Direct peers on record are Valo Health, Atomwise, XtalPi, Schrödinger, Insitro, Insilico Medicine, BenevolentAI and Isomorphic Labs. Emerging players are AbCellera and Iambic (formerly Entasis Therapeutics).

Does Recursion Pharmaceuticals have an API?

Yes. Phenom-Beta foundation model is available through NVIDIA BioNeMo Cloud API for non-commercial use, allowing developers to access the microscopy image embedding model programmatically. Developer documentation is at www.nvidia.com/en-us/clara/bionemo.

What industry is Recursion Pharmaceuticals in?

Recursion Pharmaceuticals's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeRecursion Announces FDA Alignment on Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis | RXRX Stock NewsRecursion announced FDA alignment on its Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis, with adenoma excision ≥10 mm as a primary endpoint. The trial, expected to enroll about 200 post-colectomy patients, is on track to begin in the second half of 2027.Investing.comRecursion gains FDA alignment on phase 3 trial design for FAPRecursion Pharmaceuticals reached FDA agreement on Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis. The trial will use a composite event-free survival endpoint and enroll about 200 adults, starting in the second half of 2027. FAP has no approved pharmacologic therapies.YahooRecursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous PolyposisRecursion announced FDA alignment on its registrational Phase 3 trial for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis. The trial's primary endpoint includes excision of adenomas ≥10 mm, with enrollment of ~200 patients expected to begin in the second half of 2027.TradingViewRecursion (RXRX) Gets FDA Alignment on REC-4881 Phase 3 DesignRecursion aligned with the FDA on the registrational Phase 3 design for REC-4881, with trial initiation on track for the second half of 2027. The study is expected to enroll approximately 200 patients, with a primary endpoint including qualifying adenoma excisions.FinancialContent Business PageRecursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous PolyposisRecursion announced FDA alignment on its registrational Phase 3 trial for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis. The trial's primary endpoint includes excision of adenomas ≥10 mm, with enrollment of ~200 patients expected to begin in the second half of 2027.Stock TitanRecursion aligns with FDA on REC-4881 Phase 3 designRecursion announced FDA alignment on its registrational Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis. The primary endpoint includes excision of adenomas ≥10 mm as a novel event, with the trial expected to enroll about 200 patients and begin in the second half of 2027.GlobeNewswireRecursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous PolyposisRecursion announced FDA alignment on its registrational Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis. The primary endpoint includes excision of adenomas ≥10 mm as a novel event, with the trial expected to enroll ~200 patients and begin in the second half of 2027.YahooWhat Recursion Pharmaceuticals Investors Missed Before The FallRecursion Pharmaceuticals shares fell 35.2% from the start of the year, trading at $2.72. Q3 2026 revenue was $18.6M with a net loss of $119M, while Q1 2026 revenue dropped 56% year on year. The company's AI-driven platform remains unproven commercially.Investing.comRecursion Pharmaceuticals stock hits 52-week low at 2.76 USDRecursion Pharmaceuticals stock hit a 52-week low of $2.77, down 18% in a week and 29.5% year-to-date. The company reported Q3 2026 revenue of $18.55 million, beating the $12.98 million forecast, while matching the estimated adjusted loss per share of $0.22.